<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592289</url>
  </required_header>
  <id_info>
    <org_study_id>COL-3</org_study_id>
    <nct_id>NCT04592289</nct_id>
  </id_info>
  <brief_title>Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Rectal Resections for Cancer Versus MBP Alone</brief_title>
  <acronym>REPCA</acronym>
  <official_title>Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Rectal Resections for Cancer Versus MBP Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>N.N. Petrov National Medical Research Center of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>N.N. Petrov National Medical Research Center of Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if short-term outcomes of rectal resections after&#xD;
      full bowel preparation (mechanical bowel preparation plus oral antibiotics) are superior to&#xD;
      rectal resections with only mechanical bowel preparation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design involves random allocation of eligible patients to full bowel preparation or only&#xD;
      mechanical bowel preparation in 1:1 ratio. After that rectal resection is performed in both&#xD;
      groups.&#xD;
&#xD;
      Short-term outcomes are assessed in 30 day period after surgery. This is a superiority trial&#xD;
      evaluating statistical superiority. Rate of surgical site infection is anticipated to&#xD;
      decrease from 12% (data from local registry) to 6%. For power of 80% enrolment of 622&#xD;
      patients is required.&#xD;
&#xD;
      The intent-to-treat principle is used for the data analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incisional surgical site infection (SSI) rate</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of incisional SSI in patients after rectal resections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anastomotic leak rate</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of clinical and/or radiological anastomotic leaks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraabdominal and or pelvic abscess rate</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of patients with any complications after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intraoperative complications</measure>
    <time_frame>Duration of surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery duration in minutes</measure>
    <time_frame>Duration of surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of surgery</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Assessment of procedure quality by surgeon (qualitative scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel preparation compliance</measure>
    <time_frame>Day of surgery</time_frame>
    <description>Rate of patients in experimental arm undergoing complete bowel preparation according to protocol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">622</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Full bowel preparation (MBP+OA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 400 mg twice daily for three days prior to surgery&#xD;
Day prior to surgery:&#xD;
17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml&#xD;
18.00 - 19.00 Clear fluids 500 ml&#xD;
19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml&#xD;
20.00 - 21.00 Clear fluids 500 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mechanical bowel preparation only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day prior to surgery:&#xD;
17.00 - 18.00 Macrogol-3350 - 100 g Sodium sulfate - 7,5 g Sodium chloride - 2,691 g Potassium chloride - 1,015 g Clear fluids - 1000 ml&#xD;
18.00 - 19.00 Clear fluids 500 ml&#xD;
19.00 - 20.00 Ascorbic acid - 4,7 g Sodium ascorbate - 5,9 g Clear fluids - 1000 ml&#xD;
20.00 - 21.00 Clear fluids 500 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Full bowel preparation</intervention_name>
    <description>MBP+OA</description>
    <arm_group_label>Full bowel preparation (MBP+OA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanical bowel preparation only</intervention_name>
    <description>MBP</description>
    <arm_group_label>Mechanical bowel preparation only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed adenocarcinoma of the rectum or rectosigmoid junction&#xD;
&#xD;
          -  clinical stage T1-4aN0-2M0-1 (distant metastases must be resectable)&#xD;
&#xD;
          -  indications for surgical rectal resection&#xD;
&#xD;
          -  ECOG status 0-2&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent or comply with the study protocol&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Medical contraindications for surgical treatment&#xD;
&#xD;
          -  Any use of antibiotics 30 days prior to inclusion&#xD;
&#xD;
          -  Functioning stoma&#xD;
&#xD;
          -  Contraindications for use of MBP or OA drugs or their components&#xD;
&#xD;
          -  Indications for obstructive resection or abdominoperineal excision&#xD;
&#xD;
          -  Acute bowel obstruction, bleeding or perforation&#xD;
&#xD;
          -  Other malignancies not in remission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksei Karachun</last_name>
    <role>Study Chair</role>
    <affiliation>National Medical Research Centre of Oncology named after N.N. Petrov</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksei Karachun</last_name>
    <phone>+79219462123</phone>
    <email>dr.a.karachun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleksei Petrov</last_name>
    <phone>+79214117866</phone>
    <email>alexpetrov@doctor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scientific-Research institute of Oncology named after N.N. Petrov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksei Petrov</last_name>
      <phone>+79214117866</phone>
      <email>alexpetrov@doctor.com</email>
    </contact>
    <investigator>
      <last_name>Aleksei Karachun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksei Petrov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>bowel preparation</keyword>
  <keyword>MBP</keyword>
  <keyword>Oral antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not planning to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

